BACKGROUND, Loss of heterozygosity (LOH) on chromosome arm 18q is common in
sporadic prostate cancer and may be involved in cancer development through
inactivation of tumor-suppressor genes (TSG). Recent identification, at 18
q21.1, of MADX2/Smad2, a key component in transforming growth factor beta (
TGF beta)-family signaling pathways, led us to investigate the role of this
gene in prostate tumorigenesis.
METHODS. Sporadic primary prostate tumors from 25 patients with clinically
localized tumors and 7 with metastatic forms were examined for MADX2/Smad2
mutations by using polymerase chain reaction-single-strand conformational p
olymorphism (PCR-SSCP) analysis of cDNA, and for gene expression by quantit
ative reverse transcription-polymerase chain reaction (RT-PCR).
RESULTS. We detected no mutation in MADX2/Smad2 and no abnormal mRNA expres
sion.
CONCLUSIONS. Despite recent evidence indicating that MADR2/Smad2 acts as a
tumor-suppressor gene, our findings suggest a limited role of this gene in
prostate tumorigenesis, at least in the early stages. Another key tumor-sup
pressor gene may therefore be the main target of the observed LOH at 18q21.
1. (C) 1999 Wiley-Liss, Inc.